MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 

Location: Categories / Business / Industries / Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.
Old Articles: <Older 6921-6930 Newer>
The Motley Fool
November 30, 2010
Seth Jayson
Don't Get Too Worked Up Over Agilent Technologies' Earnings With questionable cash flows amounting to only -0.7% of operating cash flow, Agilent Technologies' cash flows look clean. mark for My Articles 729 similar articles
The Motley Fool
November 30, 2010
Brian Orelli
Nice Data; Still a Long Wait for the Payoff It may not be enough to move Keryx Biopharmaceuticals' Zerenex to blockbuster status, but the data from a phase 3 trial released today sure look good enough to get it on the market. mark for My Articles 86 similar articles
The Motley Fool
November 30, 2010
Brian Orelli
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. mark for My Articles 2603 similar articles
The Motley Fool
November 30, 2010
Brian Orelli
This Fish Oil Is No Snake Oil So far, Amarin's AMR101 looks like a wonder drug, and its potential is huge. mark for My Articles 133 similar articles
The Motley Fool
November 30, 2010
Brian Orelli
RNAi Is On Sale The novel technology looks more promising at these prices. mark for My Articles 167 similar articles
The Motley Fool
November 29, 2010
Seth Jayson
Here's How Teva Pharmaceutical May Be Failing You Here's the margin picture for Teva Pharmaceutical over the past few years. mark for My Articles 1302 similar articles
The Motley Fool
November 29, 2010
Brian Orelli
Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily. mark for My Articles 531 similar articles
The Motley Fool
November 29, 2010
Seth Jayson
Check This to Find Out Whether Orthovita Is Going to Bomb For the last fully reported fiscal quarter, Orthovita's year-over-year revenue grew 4.6%, and its AR grew 9.2%. That looks OK. mark for My Articles 259 similar articles
The Motley Fool
November 29, 2010
Brian Orelli
There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain. mark for My Articles 1015 similar articles
The Motley Fool
November 29, 2010
Travis Hoium
Protalix BioTherapeutics Shares Popped: What You Need to Know Shares of biopharmaceutical company Protalix BioTherapeutics jumped 10% this morning after the company announced a European application for taliglucerase alfa. mark for My Articles 9 similar articles
<Older 6921-6930 Newer>    Return to current articles.